|
NEW INSIGHT FROM MEDICAL EXPERTS READ OUR EXPERTS COLUMN |
Our company nameN-of-Onereflects our approach to personalized cancer treatment. In a typical clinical trial, the "N" stands for the number of patients enrolled. The more patients enrolled, the higher the "N", and in general large trials identify what works in the average patient. But the more we know about cancer, the less sense it makes to treat patients as if they were "average." For example, researchers estimate that there may be 20 distinct types of breast cancer aloneeach one of which will respond best to a different type of therapy. Subtypes of other cancers are also emerging.
With us, each patient is not "average"; rather, each patient is the only "N". Our job begins with understanding as much as possible about each patient's cancer at the most fundamental levelit's molecular biology. Based on sophisticated genetic and molecular analyses of a patient's tumor, N-of-One brings to light information that helps patients and their physicians make truly informed decisions.
The explosion of cancer research has led to key advances in diagnostics and treatments. We now know that even tumors that arise in the same organ can be profoundly different at the molecular level. Figuring out the "molecular drivers" of a particular tumor may be the key to being able to slow or stop its growth. That realization has led to a new emphasis on treating cancer using specialized diagnostics to study a tumor in detail and then choosing treatments based on its molecular characteristics. This is personalized medicine.
HOW WE DO THIS: N-of-One harnesses this emerging science with a bold new model of cancer care. Our team works with a network of state-of-the-art diagnostic laboratories, leading-edge research institutions, and top cancer experts. Our team supplements, but does not replace, your own doctors. We can:
We work with each client to develop a personalized action plan based upon the individual characteristics of that patient’s cancer.
We do charge for our services. However, to serve cancer patients and their medical team with integrity, we do not profit from any laboratory testing, entry into clinical trials, or referrals to cancer centers or members of our expert network.